News

A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.

Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.

With this decision, dupilumab is now the only biologic medicine approved from infancy through adulthood for people with AD.

Late-breaking data from SLEEP 2022 show there may be biological plausibility for cardiovascular risks in excessively sleepy individuals.

The study from SLEEP 2022 is the first to explore directionality of sleep-stress relationships in a sample of perinatal women.

Even after controlling for differences in age and BMI, investigators observe a greater burden of sleep health on those who had severe COVID-19 versus the general population.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

New phase 3 data indicates that a statistically significant number of patients treated with either 8 mg twice-daily or 12 mg twice daily CTP-543 experienced greater scalp regrowth compared to those on placebo

Today in a late-breaking abstract from SLEEP 2022, data showed the reduction of slow wave activity in unmedicated adolescents with depression.

Patients with obesity who had bariatric surgery had lower rates of mortality compared to patients who did not have bariatric surgery.

Investigators observe an increased risk of dream enactment among specific subgroups of veterans with trauma.

Dr. Aric Prather and his team at UCSF are running a large study that began in March 2021 which follows healthy individuals through the COVID-19 vaccination and booster process.

Findings suggested that actigraphy may provide additional information to self-reported sleep measures in patients with rheumatoid arthritis.

Investigators believe that treatment escalation within patients with rheumatoid arthritis should utilize interventions beyond the traditional physician-patient relationship.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

Data from SLEEP 2022 suggests children with OSA may have faced worse psychosocial burden during the pandemic.

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

The findings presented at SLEEP 2022 differ from previous studies that evaluated the objective-subjective sleep patterns of this population.

The agency also granted rare pediatric disease designations for inclacumab and GBT601.

A new study from SLEEP 2022 showed asthmatic children have a 10 times greater risk of the condition, and are twice as likely to have a history of snoring.

New SUNRISE 2 data show a subjective, dose-dependent, and disease severity-dependent benefit with the insomnia therapy.

Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis (RA) prescribed a disease-modifying antirheumatic drug (DMARD), until the DMARD kicks in. Test your knowledge of bridging therapy with this quiz.

A personal history rather than a family history of psoriasis is associated with the disease activity and severity of axial joint damage.

Rituximab-arrx is similar in safety and efficacy to rituximab for patients with moderate to severe rheumatoid arthritis.

Sleep expert Aric Prather, PhD, presented a discussion at SLEEP 2022 that focused on how the immune system and sleep are related to the "ongoing and protracted" impact of the COVID-19 pandemic.

New phase 3 data from the STRATUM trial found that 80.1% of individuals treated with roflumilast foam achieved "IGA Success" compared to 59.2% of patients treated with vehicle at week 8.

The FDA-approved sleep agent was associated with ≥5% weight loss in more than one-quarter of patients in a phase 3 trial.

The mean time below range following exercise sessions was significantly lower with IGlar U300 compared to IDEG at the 100% dose.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.